This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
As a nurse, you play a critical role in the ABECMA treatment process, helping RRMM patients navigate their journey with ABECMA. Get the information and tools you need to help support your patients below.
From clinical trial data to monitoring and management information, it’s all here—so you can continue to help your patients feel comfortable and secure throughout their treatment journey.
RRMM=relapsed/refractory multiple myeloma.
ABECMA is provided as a one-time infusion containing a suspension of CAR-positive T cells in 1 or more infusion bags. The dose range is 300 to 460 x 106 CAR-positive T cells. ABECMA is an autologous product.
Lymphodepletion should begin 5 days before ABECMA is administered.
Administer the low-dose lymphodepleting chemotherapy regimen of cyclophosphamide 300 mg/m2 IV and fludarabine 30 mg/m2 IV for 3 days. ABECMA should be administered 2 days after the completion of lymphodepleting chemotherapy.
Delay the infusion of ABECMA up to 7 days if a patient has any of the following conditions:
Generally, ABECMA infusion takes 30 minutes to 1 hour.*
*ABECMA infusion usually takes up to 30 minutes for each infusion bag. A patient’s dose of ABECMA may be given in 1 or more infusion bags.
Yes; 30 to 60 minutes before ABECMA infusion, you should administer acetaminophen (650 mg orally) and diphenhydramine (12.5 mg IV or 25 to 50 mg orally, or another H1-antihistamine).
Avoid prophylactic use of dexamethasone or other systemic corticosteroids, as they may interfere with the activity of ABECMA.
Patients may leave the certified treatment center 7 days after ABECMA infusion.
ABECMA is a BMCA-directed, genetically modified autologous T cell immunotherapy, and is the first CAR T cell therapy for patients with RRMM.
BCMA=B-cell maturation antigen; CAR=chimeric antigen receptor; IV=intravenously; MOA=mechanism of action.